Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK–STAT Pathway

Total Page:16

File Type:pdf, Size:1020Kb

Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK–STAT Pathway RESEARCH ARTICLE Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK–STAT Pathway Zhaoqi Liu1,2, Ioan Filip1,2, Karen Gomez1,2, Dewaldt Engelbrecht3, Shabnum Meer4, Pooja N. Lalloo3, Pareen Patel3, Yvonne Perner5, Junfei Zhao1,2, Jiguang Wang6, Laura Pasqualucci7–9, Raul Rabadan1,2, and Pascale Willem3 Downloaded from https://bloodcancerdiscov.aacrjournals.org by guest on September 24, 2021. Copyright 2020 American Copyright 2020 by AssociationAmerican for Association Cancer Research. for Cancer Research. ABSTRACT Plasmablastic lymphoma (PBL) is an aggressive B-cell non-Hodgkin lymphoma associated with immunodeficiency in the context of human immunodeficiency virus (HIV) infection or iatrogenic immunosuppression. While a rare disease in general, the incidence is dramatically increased in regions of the world with high HIV prevalence. The molecular pathogenesis of this disease is poorly characterized. Here, we defined the genomic features of PBL in a cohort of 110 patients from South Africa (15 by whole-exome sequencing and 95 by deep targeted sequenc- ing). We identified recurrent mutations in genes of the JAK–STAT signaling pathway, includingSTAT3 (42%), JAK1 (14%), and SOCS1 (10%), leading to its constitutive activation. Moreover, 24% of cases harbored gain-of-function mutations in RAS family members (NRAS and KRAS). Comparative analysis with other B-cell malignancies uncovered PBL-specific somatic mutations and transcriptional pro- grams. We also found recurrent copy number gains encompassing the CD44 gene (37%), which encodes for a cell surface receptor involved in lymphocyte activation and homing, and was found expressed at high levels in all tested cases, independent of genetic alterations. These findings have implications for the understanding of the pathogenesis of this disease and the development of personalized medicine approaches. SIGNIFICANCE: Plasmablastic lymphoma is a poorly studied and extremely aggressive tumor. Here we define the genomic landscape of this lymphoma in HIV-positive individuals from South Africa and iden- tify pervasive mutations in JAK–STAT3 and RAS–MAPK signaling pathways. These data offer a genomic framework for the design of improved treatment strategies targeting these circuits. INTRODUCTION (HIV)-related or iatrogenic immunodeficiency (1). As an AIDS- defining illness with a dismal prognosis, PBL is a particularly Plasmablastic lymphoma (PBL) is a highly aggressive lym- compelling problem in the Sub-Saharan African region, which phoma of preterminally differentiated B cells, which predomi- accounts for approximately 54% of the estimated 37.9 million nantly occurs in patients with human immunodeficiency virus people living with HIV. Despite the national rollout offering combination anti- 1Program for Mathematical Genomics, Columbia University, New York, retroviral therapy (cART) in South Africa since 2004, the prev- 2 New York. Departments of Systems Biology and Biomedical Informatics, alence of HIV-associated mature B-cell lymphomas increases Columbia University, New York, New York. 3Department of Haematology and Molecular Medicine, National Health Laboratory Service, Faculty of yearly (2). The burden of HIV-associated lymphomas on Health Sciences, University of the Witwatersrand, Johannesburg, South the country’s encumbered health are further compounded Africa. 4Department of Oral Pathology, Faculty of Health Sciences, Uni- by the younger presentation age of HIV-infected patients, versity of the Witwatersrand, Johannesburg, South Africa. 5Department the challenging classification of these lymphomas, and an of Anatomical Pathology, National Health Laboratory Service, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South exceptionally aggressive clinical disease course that, although Africa. 6Division of Life Science, Department of Chemical and Biological curable in a significant fraction of patients (3), often results Engineering, Center for Systems Biology and Human Health and State Key in fatalities (4). Laboratory of Molecular Neuroscience, The Hong Kong University of Sci- Previously being classified as diffuse large B-cell lymphoma 7 ence and Technology, Hong Kong SAR, China. Institute for Cancer Genetics. (DLBCL), PBL was later recognized as a distinct entity (5) 8Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York. 9Department of Pathology and Cell Biology, Herbert Irving with well-defined histopathologic features including large Comprehensive Cancer Center, Columbia University, New York, New York. plasmablastic or immunoblastic cell morphology, loss of Note: Supplementary data for this article are available at Blood Cancer B-cell lineage markers (CD20, PAX5), expression of plasma- Discovery Online (http://bloodcancerdiscov.aacrjournals.org/). cytic differentiation markers (CD38, CD138, IRF4/MUM1, L. Pasqualucci, R. Rabadan, and P. Willem contributed equally to this article. BLIMP1), a high proliferation index, and frequent infection Corresponding Authors: Laura Pasqualucci, Institute for Cancer Genetics, by the Epstein-Barr virus (EBV; ref. 6). While EBV infection Columbia University, 1130 St Nicholas Ave, Room 507B, New York, NY 10032. and activating MYC translocations have been reported as Phone: 212-851-5248; Fax: 212-851-5256; E-mail: [email protected]; the major features of these tumors in a number of studies Raul Rabadan, Columbia University Irving Medical Center, 622 West 168th (7), the molecular pathology of PBL remains elusive in both Street, PH18-200, New York, NY 10032. Phone: 212-305-3896; Fax: 212- 851-5149; Email: [email protected]; and Pascale Willem, University HIV-positive and -negative individuals. Numerous case stud- of the Witwatersrand and the National Health Laboratory Service, Wits Medi- ies and some cohorts have been well described and reviewed cal School, 7 York Road Parktown, Johannesburg 2193, South Africa. Phone: (6–9). Only two studies have partially explored genetic aber- 271-1489-8406; Fax: 271-1489-8480; E-mail: [email protected] rations in this disease: a comparative genomic hybridiza- Blood Cancer Discov 2020;1–14 tion study showed a pattern of segmental gains in PBL doi: 10.1158/2643-3230.BCD-20-0051 that more closely resembled DLBCL than plasma cell mye- ©2020 American Association for Cancer Research. loma (10). The second study compared the transcriptional 2020 BLOOD CANCER DISCOVERY | OF2 Downloaded from https://bloodcancerdiscov.aacrjournals.org by guest on September 24, 2021. Copyright 2020 American Association for Cancer Research. RESEARCH ARTICLE Liu et al. profiles of 15 PBL cases to DLBCL and extraosseous plasma- PBL cohort (Fig. 1A–E). The most frequent genetic lesions cytoma (11), and showed that B-cell receptor signaling genes affected the JAK–STAT signaling pathway with, in total, including CD79A/B, BLK, LYN, and SWAP70 among others, 62% of cases (68/110) harboring a mutation in at least one were significantly downregulated in PBL compared with of five genes STAT3,( JAK1, SOCS1, JAK2, and PIM1, a direct DLBCL; in contrast, targets of MYB and the oncogene MYC, transcriptional target of STAT3/5 that functions as part of as well as genes reflecting the known plasmacytic immu- a negative feedback loop; Fig. 1A). Among these, STAT3 was nophenotype of PBL, were overexpressed. More recently, the predominant target of mutations, with 46 of 110 cases MYC and PRDM1 were investigated for mutations, struc- (42%) harboring clonal events (Supplementary Fig. S2A and tural rearrangements, and copy number gains in 36 PBL S2B). With three exceptions, the identified variants were het- cases (12). PRDM1 mutations were found in 8 of 16 cases, erozygous missense mutations clustering in exons 19 to 22, frequently in association with MYC overexpression, sug- encoding part of the SH2 domain that is required for STAT3 gesting a coordinate role in the pathogenesis of the disease. molecular activation via receptor association and tyrosine While these studies have shed light on this rare disorder, a phosphodimer formation (14). In particular, the majority systematic characterization of protein-changing alterations of the mutations resulted in the amino acid changes Y640F in PBL has not been performed. (n = 11), D661V (n = 9), S614R (n = 5), and E616G/K (n = 4; The elucidation of genes and pathways that drive the Fig. 1B), which have been categorized as gain-of-function initiation and maintenance of PBL is essential to better or likely gain-of-function mutations based on experimental understand the biology of this cancer and, critically, to imple- validation (https://oncokb.org/gene/STAT3), and overlap ment improved biomarkers and more effective treatment with the STAT3 mutation pattern described in other aggres- options. Here, we combined whole-exome and transcriptome sive B-cell lymphomas and T-cell and natural killer (NK) sequencing followed by targeted resequencing of 110 HIV- cell malignancies (15, 16). Three additional cases showed a associated PBL cases to elucidate the mutational, transcrip- >75% variant allele frequency in the absence of copy number tional, and copy number landscape of this disease. We show changes, consistent with a copy neutral loss of heterozygo- that mutations in various components of the JAK–STAT and sis. Sanger-based resequencing of the involved STAT3 exons, MAPK–ERK pathway pervade this lymphoma, revealing this performed in 23 cases, validated all computationally identi- signaling cascade as
Recommended publications
  • Abnormal Developmental Control of Replication-Timing Domains in Pediatric Acute Lymphoblastic Leukemia
    Downloaded from genome.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press Research Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia Tyrone Ryba,1,6 Dana Battaglia,1,6 Bill H. Chang,2 James W. Shirley,1 Quinton Buckley,1 Benjamin D. Pope,1 Meenakshi Devidas,3 Brian J. Druker,4,5 and David M. Gilbert1,7 1Department of Biological Science, Florida State University, Tallahassee, Florida 32306, USA; 2Division of Hematology and Oncology, Department of Pediatrics, and OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon 97239, USA; 3COG and Department of Biostatistics, College of Medicine, University of Florida, Gainesville, Florida 32601, USA; 4Division of Hematology and Medical Oncology, and OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon 97239, USA; 5Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA Abnormal replication timing has been observed in cancer but no study has comprehensively evaluated this misregulation. We generated genome-wide replication-timing profiles for pediatric leukemias from 17 patients and three cell lines, as well as normal B and T cells. Nonleukemic EBV-transformed lymphoblastoid cell lines displayed highly stable replication- timing profiles that were more similar to normal T cells than to leukemias. Leukemias were more similar to each other than to B and T cells but were considerably more heterogeneous than nonleukemic controls. Some differences were patient specific, while others were found in all leukemic samples, potentially representing early epigenetic events. Differences encompassed large segments of chromosomes and included genes implicated in other types of cancer. Remarkably, dif- ferences that distinguished leukemias aligned in register to the boundaries of developmentally regulated replication- timing domains that distinguish normal cell types.
    [Show full text]
  • Identification of Genetic Factors Underpinning Phenotypic Heterogeneity in Huntington’S Disease and Other Neurodegenerative Disorders
    Identification of genetic factors underpinning phenotypic heterogeneity in Huntington’s disease and other neurodegenerative disorders. By Dr Davina J Hensman Moss A thesis submitted to University College London for the degree of Doctor of Philosophy Department of Neurodegenerative Disease Institute of Neurology University College London (UCL) 2020 1 I, Davina Hensman Moss confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Collaborative work is also indicated in this thesis. Signature: Date: 2 Abstract Neurodegenerative diseases including Huntington’s disease (HD), the spinocerebellar ataxias and C9orf72 associated Amyotrophic Lateral Sclerosis / Frontotemporal dementia (ALS/FTD) do not present and progress in the same way in all patients. Instead there is phenotypic variability in age at onset, progression and symptoms. Understanding this variability is not only clinically valuable, but identification of the genetic factors underpinning this variability has the potential to highlight genes and pathways which may be amenable to therapeutic manipulation, hence help find drugs for these devastating and currently incurable diseases. Identification of genetic modifiers of neurodegenerative diseases is the overarching aim of this thesis. To identify genetic variants which modify disease progression it is first necessary to have a detailed characterization of the disease and its trajectory over time. In this thesis clinical data from the TRACK-HD studies, for which I collected data as a clinical fellow, was used to study disease progression over time in HD, and give subjects a progression score for subsequent analysis. In this thesis I show blood transcriptomic signatures of HD status and stage which parallel HD brain and overlap with Alzheimer’s disease brain.
    [Show full text]
  • A Genome Wide Screen in C. Elegans Identifies Cell Non-Autonomous Regulators of Oncogenic Ras Mediated Over-Proliferation DISSER
    A genome wide screen in C. elegans identifies cell non-autonomous regulators of oncogenic Ras mediated over-proliferation DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Komal Rambani Graduate Program in Biomedical Sciences The Ohio State University 2016 Dissertation Committee: Gustavo Leone, PhD “Advisor" Helen Chamberlin, PhD Gregory Lesinski, PhD Joanna Groden, PhD Jeffrey Parvin, PhD Thomas Ludwig, PhD Copyright by Komal Rambani 2016 ABSTRACT Coordinated proliferative signals from the mesenchymal cells play a crucial role in the regulation of proliferation of epithelial cells during normal development, wound healing and several other normal physiological conditions. However, when epithelial cells acquire a set of malignant mutations, they respond differently to these extrinsic proliferative signals elicited by the surrounding mesenchymal cells. This scenario leads to a pathological signaling microenvironment that enhances abnormal proliferation of mutant epithelial cells and hence tumor growth. Despite mounting evidence that mesenchymal (stromal) cells influence the growth of tumors and cancer progression, it is unclear which specific genes in the mesenchymal cells regulate the molecular signals that promote the over-proliferation of the adjacent mutant epithelial cells. We hypothesized that there are certain genes in the mesenchymal (stromal) cells that regulate proliferation of the adjacent mutant cells. The complexity of various stromal cell types and their interactions in vivo in cancer mouse models and human tumor samples limits our ability to identify mesenchymal genes important in this process. Thus, we took a cross-species approach to use C. elegans vulval development as a model to understand the impact of mesenchymal (mesodermal) cells on the proliferation of epithelial (epidermal) cells.
    [Show full text]
  • Genomic Mapping of the MHC Transactivator CIITA Using An
    Wong et al. Genome Biology 2014, 15:494 http://genomebiology.com/2014/15/10/494 RESEARCH Open Access Genomic mapping of the MHC transactivator CIITA using an integrated ChIP-seq and genetical genomics approach Daniel Wong1†, Wanseon Lee1†, Peter Humburg1, Seiko Makino1, Evelyn Lau1, Vivek Naranbhai1, Benjamin P Fairfax1, Kenneth Chan2, Katharine Plant1 and Julian C Knight1* Abstract Background: The master transactivator CIITA is essential to the regulation of Major Histocompatibility Complex (MHC) class II genes and an effective immune response. CIITA is known to modulate a small number of non-MHC genes involved in antigen presentation such as CD74 and B2M but its broader genome-wide function and relationship with underlying genetic diversity has not been resolved. Results: We report the first genome-wide ChIP-seq map for CIITA and complement this by mapping inter-individual variation in CIITA expression as a quantitative trait. We analyse CIITA recruitment for pathophysiologically relevant primary human B cells and monocytes, resting and treated with interferon-gamma, in the context of the epigenomic regulatory landscape and DNA-binding proteins associated with the CIITA enhanceosome including RFX, CREB1/ATF1 and NFY. We confirm recruitment to proximal promoter sequences in MHC class II genes and more distally involving the canonical CIITA enhanceosome. Overall, we map 843 CIITA binding intervals involving 442 genes and find 95% of intervals are located outside the MHC and 60% not associated with RFX5 binding. Binding intervals are enriched for genes involved in immune function and infectious disease with novel loci including major histone gene clusters. We resolve differentially expressed genes associated in trans with a CIITA intronic sequence variant, integrate with CIITA recruitment and show how this is mediated by allele-specific recruitment of NF-kB.
    [Show full text]
  • The Human Canonical Core Histone Catalogue David Miguel Susano Pinto*, Andrew Flaus*,†
    bioRxiv preprint doi: https://doi.org/10.1101/720235; this version posted July 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. The Human Canonical Core Histone Catalogue David Miguel Susano Pinto*, Andrew Flaus*,† Abstract Core histone proteins H2A, H2B, H3, and H4 are encoded by a large family of genes dis- tributed across the human genome. Canonical core histones contribute the majority of proteins to bulk chromatin packaging, and are encoded in 4 clusters by 65 coding genes comprising 17 for H2A, 18 for H2B, 15 for H3, and 15 for H4, along with at least 17 total pseudogenes. The canonical core histone genes display coding variation that gives rise to 11 H2A, 15 H2B, 4 H3, and 2 H4 unique protein isoforms. Although histone proteins are highly conserved overall, these isoforms represent a surprising and seldom recognised variation with amino acid identity as low as 77 % between canonical histone proteins of the same type. The gene sequence and protein isoform diversity also exceeds com- monly used subtype designations such as H2A.1 and H3.1, and exists in parallel with the well-known specialisation of variant histone proteins. RNA sequencing of histone transcripts shows evidence for differential expression of histone genes but the functional significance of this variation has not yet been investigated. To assist understanding of the implications of histone gene and protein diversity we have catalogued the entire human canonical core histone gene and protein complement.
    [Show full text]
  • A Multiprotein Occupancy Map of the Mrnp on the 3 End of Histone
    Downloaded from rnajournal.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press A multiprotein occupancy map of the mRNP on the 3′ end of histone mRNAs LIONEL BROOKS III,1 SHAWN M. LYONS,2 J. MATTHEW MAHONEY,1 JOSHUA D. WELCH,3 ZHONGLE LIU,1 WILLIAM F. MARZLUFF,2 and MICHAEL L. WHITFIELD1 1Department of Genetics, Dartmouth Geisel School of Medicine, Hanover, New Hampshire 03755, USA 2Integrative Program for Biological and Genome Sciences, University of North Carolina, Chapel Hill, North Carolina 27599, USA 3Department of Computer Science, University of North Carolina, Chapel Hill, North Carolina 27599, USA ABSTRACT The animal replication-dependent (RD) histone mRNAs are coordinately regulated with chromosome replication. The RD-histone mRNAs are the only known cellular mRNAs that are not polyadenylated. Instead, the mature transcripts end in a conserved stem– loop (SL) structure. This SL structure interacts with the stem–loop binding protein (SLBP), which is involved in all aspects of RD- histone mRNA metabolism. We used several genomic methods, including high-throughput sequencing of cross-linked immunoprecipitate (HITS-CLIP) to analyze the RNA-binding landscape of SLBP. SLBP was not bound to any RNAs other than histone mRNAs. We performed bioinformatic analyses of the HITS-CLIP data that included (i) clustering genes by sequencing read coverage using CVCA, (ii) mapping the bound RNA fragment termini, and (iii) mapping cross-linking induced mutation sites (CIMS) using CLIP-PyL software. These analyses allowed us to identify specific sites of molecular contact between SLBP and its RD-histone mRNA ligands. We performed in vitro crosslinking assays to refine the CIMS mapping and found that uracils one and three in the loop of the histone mRNA SL preferentially crosslink to SLBP, whereas uracil two in the loop preferentially crosslinks to a separate component, likely the 3′hExo.
    [Show full text]
  • Supplemental Data.Pdf
    Supplementary material -Table of content Supplementary Figures (Fig 1- Fig 6) Supplementary Tables (1-13) Lists of genes belonging to distinct biological processes identified by GREAT analyses to be significantly enriched with UBTF1/2-bound genes Supplementary Table 14 List of the common UBTF1/2 bound genes within +/- 2kb of their TSSs in NIH3T3 and HMECs. Supplementary Table 15 List of gene identified by microarray expression analysis to be differentially regulated following UBTF1/2 knockdown by siRNA Supplementary Table 16 List of UBTF1/2 binding regions overlapping with histone genes in NIH3T3 cells Supplementary Table 17 List of UBTF1/2 binding regions overlapping with histone genes in HMEC Supplementary Table 18 Sequences of short interfering RNA oligonucleotides Supplementary Table 19 qPCR primer sequences for qChIP experiments Supplementary Table 20 qPCR primer sequences for reverse transcription-qPCR Supplementary Table 21 Sequences of primers used in CHART-PCR Supplementary Methods Supplementary Fig 1. (A) ChIP-seq analysis of UBTF1/2 and Pol I (POLR1A) binding across mouse rDNA. UBTF1/2 is enriched at the enhancer and promoter regions and along the entire transcribed portions of rDNA with little if any enrichment in the intergenic spacer (IGS), which separates the rDNA repeats. This enrichment coincides with the distribution of the largest subunit of Pol I (POLR1A) across the rDNA. All sequencing reads were mapped to the published complete sequence of the mouse rDNA repeat (Gene bank accession number: BK000964). The graph represents the frequency of ribosomal sequences enriched in UBTF1/2 and Pol I-ChIPed DNA expressed as fold change over those of input genomic DNA.
    [Show full text]
  • A Novel Histone H4 Variant Regulates Rdna Transcription in Breast Cancer
    bioRxiv preprint doi: https://doi.org/10.1101/325811; this version posted May 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. A novel histone H4 variant regulates rDNA transcription in breast cancer 1# 1# 1 1 Mengping Long , Xulun Sun , Wenjin Shi , Yanru An , Tsz Chui Sophia Leung1, 2 3 2 Dongbo Ding1, Manjinder S. Cheema , Nicol MacPherson , Chris Nelson , Juan 2 1 1 Ausio , Yan Yan , and Toyotaka Ishibashi * 1Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, NT, Hong Kong, HKSAR, China 2 Department of Biochemistry and Microbiology, University of Victoria, Victoria BC, Canada 3 Department of Medical Oncology BC Cancer, Vancouver Island Centre, Victoria, BC, Canada # These authors contributed equally to this work *correspondence: [email protected] Key Words Histone variant, histone H4, rDNA transcription, breast cancer, nucleophosmin bioRxiv preprint doi: https://doi.org/10.1101/325811; this version posted May 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Histone variants, present in various cell types and tissues, are known to exhibit different functions. For example, histone H3.3 and H2A.Z are both involved in gene expression regulation, whereas H2A.X is a specific variant that responds to DNA double-strand breaks. In this study, we characterized H4G, a novel hominidae-specific histone H4 variant. H4G expression was found in a variety of cell lines and was particularly overexpressed in the tissues of breast cancer patients.
    [Show full text]
  • Primate-Specific Histone Variants
    Genome Primate-specific histone variants Journal: Genome Manuscript ID gen-2020-0094.R1 Manuscript Type: Mini Review Date Submitted by the 16-Sep-2020 Author: Complete List of Authors: Ding, Dongbo; Hong Kong University of Science and Technology School of Science, Division of Life Science NGUYEN, Thi Thuy; Hong Kong University of Science and Technology School of Science, Division of Life Science Pang, Matthew Yu Hin; Hong Kong University of Science and Technology School of Science, Division of Life Science Ishibashi, DraftToyotaka; Hong Kong University of Science and Technology School of Science, Division of Life Science Keyword: histone variant, H2BFWT, H3.5, H3.X, H3.Y Is the invited manuscript for consideration in a Special Genome Biology Issue? : © The Author(s) or their Institution(s) Page 1 of 28 Genome 1 Primate-specific histone variants 2 Dongbo Ding1, Thi Thuy Nguyen1, Matthew Y.H. Pang1 and Toyotaka 3 Ishibashi1 4 1. Division of Life Science, The Hong Kong University of Science and Technology, 5 Clear Water Bay, NT, HKSAR, China 6 7 8 9 10 11 12 Draft 13 14 15 16 17 18 19 Correspondence should be addressed to : 20 Toyotaka Ishibashi 21 The Hong Kong University of Science and Technology 22 Clear Water Bay, NT, HKSAR, China 23 E-mail: [email protected] 24 Phone: +852-3469-2238 25 Fax: +852-2358-1552 26 © The Author(s) or their Institution(s) Genome Page 2 of 28 27 Abstract 28 29 Canonical histones (H2A, H2B, H3, and H4) are present in all eukaryotes where they 30 package genomic DNA and participate in numerous cellular processes, such as 31 transcription regulation and DNA repair.
    [Show full text]
  • The Changing Chromatome As a Driver of Disease: a Panoramic View from Different Methodologies
    The changing chromatome as a driver of disease: A panoramic view from different methodologies Isabel Espejo1, Luciano Di Croce,1,2,3 and Sergi Aranda1 1. Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain 2. Universitat Pompeu Fabra (UPF), Barcelona, Spain 3. ICREA, Pg. Lluis Companys 23, Barcelona 08010, Spain *Corresponding authors: Luciano Di Croce ([email protected]) Sergi Aranda ([email protected]) 1 GRAPHICAL ABSTRACT Chromatin-bound proteins regulate gene expression, replicate and repair DNA, and transmit epigenetic information. Several human diseases are highly influenced by alterations in the chromatin- bound proteome. Thus, biochemical approaches for the systematic characterization of the chromatome could contribute to identifying new regulators of cellular functionality, including those that are relevant to human disorders. 2 SUMMARY Chromatin-bound proteins underlie several fundamental cellular functions, such as control of gene expression and the faithful transmission of genetic and epigenetic information. Components of the chromatin proteome (the “chromatome”) are essential in human life, and mutations in chromatin-bound proteins are frequently drivers of human diseases, such as cancer. Proteomic characterization of chromatin and de novo identification of chromatin interactors could thus reveal important and perhaps unexpected players implicated in human physiology and disease. Recently, intensive research efforts have focused on developing strategies to characterize the chromatome composition. In this review, we provide an overview of the dynamic composition of the chromatome, highlight the importance of its alterations as a driving force in human disease (and particularly in cancer), and discuss the different approaches to systematically characterize the chromatin-bound proteome in a global manner.
    [Show full text]
  • WO 2013/095793 Al 27 June 2013 (27.06.2013) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/095793 Al 27 June 2013 (27.06.2013) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2012/063579 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 5 November 20 12 (05 .11.20 12) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 61/579,530 22 December 201 1 (22. 12.201 1) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: AVEO PHARMACEUTICALS, INC. kind of regional protection available): ARIPO (BW, GH, [US/US]; 75 Sidney Street, Fourth Floor, Cambridge, MA GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 02139 (US).
    [Show full text]
  • On Predicting Lung Cancer Subtypes Using
    Pineda et al. BMC Cancer (2016) 16:184 DOI 10.1186/s12885-016-2223-3 RESEARCH ARTICLE Open Access On Predicting lung cancer subtypes using ‘omic’ data from tumor and tumor-adjacent histologically-normal tissue Arturo López Pineda1*, Henry Ato Ogoe1, Jeya Balaji Balasubramanian1, Claudia Rangel Escareño2, Shyam Visweswaran1, James Gordon Herman3 and Vanathi Gopalakrishnan1 Abstract Background: Adenocarcinoma (ADC) and squamous cell carcinoma (SCC) are the most prevalent histological types among lung cancers. Distinguishing between these subtypes is critically important because they have different implications for prognosis and treatment. Normally, histopathological analyses are used to distinguish between the two, where the tissue samples are collected based on small endoscopic samples or needle aspirations. However, the lack of cell architecture in these small tissue samples hampers the process of distinguishing between the two subtypes. Molecular profiling can also be used to discriminate between the two lung cancer subtypes, on condition that the biopsy is composed of at least 50 % of tumor cells. However, for some cases, the tissue composition of a biopsy might be a mix of tumor and tumor-adjacent histologically normal tissue (TAHN). When this happens, a new biopsy is required, with associated cost, risks and discomfort to the patient. To avoid this problem, we hypothesize that a computational method can distinguish between lung cancer subtypes given tumor and TAHN tissue. Methods: Using publicly available datasets for gene expression and DNA methylation, we applied four classification tasks, depending on the possible combinations of tumor and TAHN tissue. First, we used a feature selector (ReliefF/Limma) to select relevant variables, which were then used to build a simple naïve Bayes classification model.
    [Show full text]